Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Immunotherapy in Anti-Hu Paraneoplastic Sensory Neuronopathy
NCT06373211Phase 2Recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jan 2025
- Primary completion
- Jun 2028
- Modality
- Recombinant Proteins and Enzymes, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of intravenous immunoglobulin G, cyclophosphamide, methylprednisolone injection in paraneoplastic sensory neuronopathy (PSN), sponsored by Assistance publique - Hôpitaux de Paris. Started Jan 2025; status: recruiting.
02
Drugs
intravenous immunoglobulin Gcyclophosphamidemethylprednisolone injection
03
Conditions
paraneoplastic sensory neuronopathy (PSN)
Beyond the preview
Go deeper on NCT06373211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06373211.